FACE IPF HEAD ON and modify disease progression by slowing lung function decline How to identify patients with RA-ILD who can benefit from OFEV 07/07/2025 | Author: Boehringer Ingelheim Document ID: PC-KW-100729 | Expiry Date: 23/10/2026 New PPF Guidelines The Need to Act in the Face of Progression How to identify patients with RA-ILD who can benefit from OFEV The Threat of Pulmonary Fibrosis Across A range of ILDs RELATED CONTENT Read more 1:11 The Threat of Pulmonary Fibrosis Across A range of ILDs PC-KW-100823 (January 2028 ) Watch now Opens in new tab Read more PDF The Need to Act in the Face of Progression PC-KW-100734 (November 2026 ) Download Opens in new tab Home OFEV How to identify patients with RA-ILD who can benefit from OFEV
Read more 1:11 The Threat of Pulmonary Fibrosis Across A range of ILDs PC-KW-100823 (January 2028 ) Watch now Opens in new tab
Read more PDF The Need to Act in the Face of Progression PC-KW-100734 (November 2026 ) Download Opens in new tab
